Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 05, 2022

SELL
$57.92 - $72.58 $269,501 - $337,714
-4,653 Closed
0 $0
Q2 2021

Aug 04, 2021

SELL
$63.47 - $69.35 $9,076 - $9,917
-143 Reduced 2.98%
4,653 $320,000
Q1 2021

May 11, 2021

BUY
$60.0 - $68.46 $287,760 - $328,334
4,796 New
4,796 $310,000
Q4 2018

Feb 08, 2019

SELL
$60.54 - $79.0 $169,572 - $221,279
-2,801 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$71.28 - $78.92 $199,655 - $221,054
2,801 New
2,801 $217,000
Q2 2018

Aug 08, 2018

SELL
$64.88 - $75.68 $224,290 - $261,625
-3,457 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$72.84 - $88.8 $251,807 - $306,981
3,457 New
3,457 $261,000
Q4 2017

Feb 07, 2018

SELL
$71.15 - $83.52 $248,953 - $292,236
-3,499 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$72.11 - $85.47 $1,874 - $2,222
26 Added 0.75%
3,499 $283,000
Q2 2017

Aug 15, 2017

BUY
N/A
3,473
3,473 $246,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $85.7B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Wilbanks Smith & Thomas Asset Management LLC Portfolio

Follow Wilbanks Smith & Thomas Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wilbanks Smith & Thomas Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wilbanks Smith & Thomas Asset Management LLC with notifications on news.